Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of ca 19-9 and carcinoembryonic antigen

Chinese Medical Journal

Volumn 127, Issue 12, 2014, Pages 2299-2303

  Yu, Tu Nan ^a   Yu, Hong ^a   Cai, Xiu Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

CA 19 9 antigen blood; Carcinoembryonic antigen blood; Gallbladder neoplasms surgery

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHOLECYSTECTOMY; CLINICAL EXAMINATION; CLINICAL FEATURE; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; GALLBLADDER TUMOR; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84902437032     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131734     Document Type: Article

References (27)

1. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010; 15: 168-181.
2. Blalock A. A statistical study of 888 cases of biliary tract disease. Johns Hopkins Hosp Bull 1924; 35: 391-409.
3. Liang JW, Dong SX, Zhou ZX, Tian YT, Zhao DB, Wang Cf, et al. Surgical management for carcinoma of the gallbladder: a single-institution experience in 25 years. Chin Med J 2008; 121: 1900-1905.
4. Feng FL, Liu C, Li B, Zhang BH, Jiang XQ. Role of radical resection in patients with gallbladder carcinoma and jaundice. Chin Med J 2012; 125: 752-756.
5. Nishio H, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection. Ann Surg 2011; 253: 953-960.
6. Sakata J, Shirai Y, Wakai T, Ajioka Y, Hatakeyama K. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol 2010; 17: 1831-1840.
7. Sakamoto Y, Nara S, Kishi Y, Esaki M, Shimada K, Kokudo N, et al. Is extended hemihepatectomy plus pancreaticoduodenectomy justifed for advanced bile duct cancer and gallbladder cancer? Surgery 2013; 153:794-800.
8. Fong Y, Wagman L, Gonen M, Crawford J, Reed W, Swanson R, et al. Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. Ann Surg 2006; 243: 767-771. discussion 771-764.
9. Onoyama H, Yamamoto M, Tseng A, Ajiki T, Saitoh Y. Extended cholecystectomy for carcinoma of the gallbladder. World J Surg 1995; 19: 758-763.
10. Donohue JH, Nagorney DM, Grant CS, Tsushima K, Ilstrup DM, Adson MA. Carcinoma of the gallbladder: does radical resection improve outcome? Arch Surg 1990; 125: 237-241.
11. Ohtani T, Shirai Y, Tsukada K, Hatakeyama K, Muto T. Carcinoma of the gallbladder: CT evaluation of lymphatic spread. Radiology 1993; 189: 875-880.
12. Kim JH, Kim TK, Eun HW, Kim BS, Lee MG, Kim PN, et al. Preoperative evaluation of gallbladder carcinoma: efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging 2002; 16: 676-684.
13. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45: 43-50.
14. Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M. Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and fow-cytometric study of twenty cases. Jpn J Cancer Res 1994; 85: 389-399.
15. Oohashi Y, Shirai Y, Wakai T, Nagakura S, Watanabe H, Hatakeyama K. Adenosquamous carcinoma of the gallbladder warrants resection only if curative resection is feasible. Cancer 2002; 94: 3000-3005.
16. You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg 2008; 247: 835-838.
17. Kondo S, Nimura Y, Hayakawa N, Kamiya J, Nagino M, Uesaka K. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg 2000; 87: 418-422.
18. Ohtani T, Shirai Y, Tsukada K, Muto T, Hatakeyama K. Spread of gallbladder carcinoma: CT evaluation with pathologic correlation. Abdom Imaging 1996; 21: 195-201.
19. Goere D, Wagholikar GD, Pessaux P, Carrere N, Sibert A, Vilgrain V, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006; 20: 721-725.
20. Abbruzzese JL. Molecular diagnosis of pancreatic and biliary cancer: ready for broad implementation? Cancer J 2000; 6: 282-284.
21. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012; 23: 1713-1722.
22. Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O. Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 2097-2100.
23. Shukla PJ, Neve R, Barreto SG, Hawaldar R, Nadkarni MS, Mohandas KM, et al. A new scoring system for gallbladder cancer (aiding treatment algorithm): an analysis of 335 patients. Ann Surg Oncol 2008; 15: 3132-3137.
24. Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford) 2010; 12: 134-138.
25. Chakravarty KD, Yeh CN, Jan YY, Chen MF. Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 2009; 79: 151-157.
26. Chen YF, Mai CR, Tie ZJ, Feng ZT, Zhang J, Lu XH, et al. The diagnostic signifcance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma. Chin Med J 1989; 102: 333-337.
27. Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg 2011; 45: 301-321.